Over the last 4 years, the ACO & Emerging Healthcare Delivery Coalition has continued to grow as a result of the opportunities to hear about innovations in accountable care organizations (ACOs) and to network with a diverse group of people, said Anthony Slonim, MD, DrPH, president and CEO of Renown Health and chair of the ACO Coalition.
Over the last 4 years, the ACO & Emerging Healthcare Delivery Coalition has continued to grow as a result of the opportunities to hear about innovations in accountable care organizations (ACOs) and to network with a diverse group of people, said Anthony Slonim, MD, DrPH, president and CEO of Renown Health and chair of the ACO Coalition.
Transcript
How has the ACO Coalition grown and evolved since its inception?
The ACO Coalition continues to grow. We have more members and more diverse members than we've ever had over the course of our 4 years. And I think that's a testament to what people get when they come to a meeting. They get an opportunity to hear cutting edge work that's innovative. They get to not only understand what people are doing at the research level, but how they apply it in their own ACO. And the networking opportunities are incomparable to anywhere else in the places where you go to get networking.
It's just an amazing place to be and a great opportunity to come together a couple of times a year. And to keep that momentum going, even in between the live meetings.
The ACO Coalition, while it continues to grow in size and diversity, is a place where we like to showcase innovation. So if you have innovative ideas about how you're running your ACO, or how you are advancing the health of your community or the population that you serve, bring it on. We'd love to hear about it and share it with our members.
Blister Packs May Help Solve Medication Adherence Challenges and Lower Health Care Costs
June 10th 2025Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.
Listen
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More
Moving Evidence From Research to Practice: Q&A With Ken Cohen, MD
June 23rd 2025In 2025, each issue of Population Health, Equity & Outcomes will feature a profile of a health system leader transforming care in their area of expertise. This issue spotlights a conversation with Ken Cohen, MD, executive director of translational research at Optum Health.
Read More